Document is current

Article History

Accepted: 14 June 2021

First Online: 23 October 2021

Declarations

:

: Kaitlyn Melnick declares that she has no conflict of interest.David Shin declares that he has no conflict of interest.Farhad Dastmalchi declares that he has no conflict of interest.Zain Kabeer declares that he has no conflict of interest.Rahman: PI of the TORCH study (NCT04187872) studying LITT and PD-1 blockade for recurrent brain metastases. Sponsored by Monteris Medical. Dr. Rahman receives no direct funding for this study.Tran: David D. Tran has received research funding from Sarepta, Novocure, Lacerta Therapeutics, Merck, Novartis, Monteris Medical, Tocagen, Advanced BioScience Laboratories (ABL), and Stemline Therapeutics; has received compensation from Novocure and Monteris Medical for participation on medical advisory boards; has received reimbursement for travel expenses from Novartis; and has the following patents pending:* “Inhibiting Prostaglandin E Receptor 3 Resensitizes Resistant Cells to TTFields”.* “Methods for Reducing Viability of Cancer Cells by Activation of the STING Pathway with TTFields”.* “AAV capsid variants targeting human glioblastoma stemlike cells” (licensed to Lacerta Therapeutics).* “Core Master Regulators of Glioblastoma Stem Cells”.* “Methods for Targeted Treatment and Prediction of Patient Survival in Cancer”.* “Methods for Cancer Screening and Monitoring by Cancer Master Regulators Markers in Liquid Biopsy”.* “Immunotherapy for Direct Reprogramming of Cancer Cells into Immune Cells/Antigen Presenting Cells/Dendritic Cells”.^* “GeneRep and nSCORE: Method and Apparatus for Improved Determination of Node Influence in a Network”.Ghiaseddin: Ashley P. Ghiaseddin has received research funding from Orbus Therapeutics and has received compensation from Novocure and Monteris Medical for participation on medical advisory boards.